Mostrar el registro sencillo del ítem
dc.contributor.author
Ortiz Moyano, Francisco Ramiro
dc.contributor.author
Raya Tonetti, María Fernanda
dc.contributor.author
Fukuyama, Kohtaro
dc.contributor.author
Elean, Mariano Daniel
dc.contributor.author
Tomokiyo, Mikado
dc.contributor.author
Suda, Yoshihito
dc.contributor.author
Melnikov, Vyacheslav
dc.contributor.author
Kitazawa, Haruki
dc.contributor.author
Villena, Julio Cesar
dc.date.available
2024-04-22T13:49:51Z
dc.date.issued
2023-03
dc.identifier.citation
Ortiz Moyano, Francisco Ramiro; Raya Tonetti, María Fernanda; Fukuyama, Kohtaro; Elean, Mariano Daniel; Tomokiyo, Mikado; et al.; The Respiratory Commensal Bacterium Corynebacterium pseudodiphtheriticum as a Mucosal Adjuvant for Nasal Vaccines; MDPI; Vaccines; 11; 3; 3-2023; 1-14
dc.identifier.issn
2076-393X
dc.identifier.uri
http://hdl.handle.net/11336/233756
dc.description.abstract
Previously, we demonstrated that nasally administered Corynebacterium pseudodiphteriticum 090104 (Cp) or its bacterium-like particles (BLPs) increase the resistance of mice against bacterial and viral respiratory pathogens by modulating the innate immunity. In this work, we evaluated the ability of Cp and BLPs to stimulate alveolar macrophages, and to enhance the humoral immune response induced by a commercial vaccine against Streptococcus pneumoniae. In the first set of experiments, Cp or the BLPs were incubated with primary cultures of murine alveolar macrophages and the phagocytic activity, and the production of cytokines was evaluated. The results revealed that Cp and BLPs were efficiently phagocyted by respiratory macrophages and that both treatments triggered the production of TNF-α, IFN-γ, IL-6, and IL-1β. In the second set of experiments, 3-week-old Swiss mice were intranasally immunized at days 0, 14, and 28 with the pneumococcal vaccine Prevenar®13 (PCV), Cp + PCV, or BLPs + PCV. On day 33, samples of bronco-alveolar lavages (BAL) and serum were collected for the study of specific antibodies. In addition, immunized mice were challenged with S. pneumoniae serotypes 6B or 19F on day 33 and sacrificed on day 35 (day 2 post-infection) to evaluate the resistance to the infection. Both Cp + PCV and BLPs + PCV groups had higher specific serum IgG and BAL IgA antibodies than the PCV control mice. In addition, the mice that were immunized with Cp + PCV or BLPs + PCV had lower lung and blood pneumococcal cell counts as well as lower levels of BAL albumin and LDH, indicating a reduced lung damage compared to the control mice. Improved levels of anti-pneumococcal antibodies were also detected in the serum and BAL samples after the challenges with the pathogens. The results demonstrated that C. pseudodiphteriticum 090104 and its bacterium-like particles are capable of stimulating the respiratory innate immune system serving as adjuvants to potentiate the adaptive humoral immune response. Our study is a step forward in the positioning of this respiratory commensal bacterium as a promising mucosal adjuvant for vaccine formulations aimed at combating respiratory infectious diseases.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
MDPI
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
CORYNEBACTERIUM PSEUDODIPHTERITICUM
dc.subject
BACTERIUM-LIKE PARTICLES
dc.subject
MUCOSAL ADJUVANT
dc.subject
RESPIRATORY INFECTION
dc.subject
ALVEOLAR MACROPHAGES
dc.subject.classification
Inmunología
dc.subject.classification
Medicina Básica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
The Respiratory Commensal Bacterium Corynebacterium pseudodiphtheriticum as a Mucosal Adjuvant for Nasal Vaccines
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2024-04-22T11:47:54Z
dc.journal.volume
11
dc.journal.number
3
dc.journal.pagination
1-14
dc.journal.pais
Suiza
dc.journal.ciudad
Basel
dc.description.fil
Fil: Ortiz Moyano, Francisco Ramiro. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
dc.description.fil
Fil: Raya Tonetti, María Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
dc.description.fil
Fil: Fukuyama, Kohtaro. Tohoku University; Japón
dc.description.fil
Fil: Elean, Mariano Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
dc.description.fil
Fil: Tomokiyo, Mikado. Tohoku University; Japón
dc.description.fil
Fil: Suda, Yoshihito. Miyagi University; Japón
dc.description.fil
Fil: Melnikov, Vyacheslav. No especifíca;
dc.description.fil
Fil: Kitazawa, Haruki. Tohoku University; Japón
dc.description.fil
Fil: Villena, Julio Cesar. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
dc.journal.title
Vaccines
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2076-393X/11/3/611
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3390/vaccines11030611
Archivos asociados